Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver entities : Can-fite biopharma ltd save search
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 4.76%
H: 0.45%
C: -5.91%
drug candidate liver cancer treat namodenoson advanced
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: -0.45%
H: 2.27%
C: 2.27%
europe liver conference distribution pancreatic treatment namodenoson
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
Published: 2023-07-17 (Crawled : 13:00) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 1.97%
H: 2.43%
C: 0.32%
award liver granted asco cancer treatment namodenoson
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
Published: 2023-03-13 (Crawled : 12:00) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 10.08%
H: 0.0%
C: -7.69%
namodenoson cirrhosis liver
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
Published: 2022-10-25 (Crawled : 12:00) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 11.49%
H: 2.25%
C: -1.32%
meeting clearance namodenoson liver cancer
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
Published: 2022-08-23 (Crawled : 12:00) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 3.37%
H: 6.52%
C: 3.65%
treatment drug liver approved cancer a3ar namodenoson
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
Published: 2022-05-02 (Crawled : 12:00) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 9.47%
H: 0.0%
C: -6.39%
ceo liver immunotherapy cancer namodenoson
Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
Published: 2022-03-14 (Crawled : 12:30) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 6.19%
H: 4.85%
C: -8.49%
treatment fibrosis patent liver namodenoson
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
Published: 2021-12-29 (Crawled : 12:30) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 16.67%
H: 0.0%
C: -1.36%
treatment clearance solid tumors application patent liver cancer
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
Published: 2021-12-20 (Crawled : 12:30) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 88.98%
H: 8.33%
C: -10.42%
liver cancer namodenoson
Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study
Published: 2021-07-08 (Crawled : 12:00) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: -4.91%
H: 7.54%
C: 5.16%
cancer liver
New Positive Data from Can-Fite’s Liver Cancer Phase II Clinical Study with Namodenoson
Published: 2021-02-22 (Crawled : 14:00) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 20.0%
H: 5.67%
C: -10.28%
positive cancer liver namodenoson
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
KUKE | $2.88 2.49% 7.64% 360K
|
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
BSBR | $5.25 2.54% 0.38% 430K
|
Finance
JOE 4 | $54.88 1.22% 0.22% 210K
|
Finance
MUSA 4 | $417.23 1.06% 0.01% 170K
|
Retail Trade
JBI 4 | $15.14 1.34% 0.0% 2.9M
|
Your saved searches
Save your searches and get alerts when important news are released.